AbbVie Inc. (ABBV)财务
NYSE · Healthcare · Drug Manufacturers - General · 员工57,000人 · CEO Robert A. Michael
- 股价
- $294.89 +1.41%
- 市值
- $5210亿
- 企业价值
- $5850亿
- 最近财报
- Q3 '26 2026-09-30提交
- 下次财报
- 2027-02-03 EPS预期 $3.90
营收(TTM)$660亿+10.7% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)35.5%+20.4 百分点 对比去年同期营业利润 $235亿
净利润(TTM)$104亿+333.4% 对比去年同期税后,含营业外收益
自由现金流(TTM)–– 对比去年同期资本支出 –
稀释EPS(TTM)$5.83+338.0% 对比去年同期最近4个季度之和
净现金-$643亿-0.4% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $5210亿 EV $5850亿
- 营收
- $660亿 过去12个月
- 营收增速
- +11% FY2026年一致预期
- 净利润率
- 15.7% 净利润 / 营收,TTM
- P/E
- 50.6× 预期 21.2×(FY2026)
- P/S
- 7.9× 股价 / 营收,TTM
- EV / EBITDA
- 24.2× TTM
- 自由现金流
- – 过去12个月
- 净利润
- $104亿 过去12个月
- 营收预期
- $676亿 FY2026年一致预期
- 盈利
- 2027-02-03 营收预期 $183亿
- 股息
- $6.92 每股,过去12个月
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-10-30):营收超预期0.5%,EPS 超预期2.4%营收$174亿,预期$173亿(+0.5%);EPS $3.82,预期$3.73(+2.4%)。
- 营收增长平稳:同比10.3%Q3 '26营收$174亿,此前四个季度的平均值为10.4%。
- 营业利润率35.5%(TTM),较去年同期+20.4 百分点营收增长10.7%,营业利润增长159.5%。
- 税前利润的83.1%被营业外亏损吞噬税前利润$128亿,营业利润$235亿(TTM)。股权投资亏损等一次性项目压低了净利润和EPS,营业利润更能反映业务本身。
- 稀释股数一年内增加0.0%Q3 '26稀释股数17.7亿,一年前为17.7亿。
- 净债务 $643亿现金 + 短期投资 $65.7亿,含租赁债务 $708亿;一年前净债务 $640亿。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $174亿 | $158亿 | +10.3% |
| 毛利率 | 85.0% | 66.4% | +18.6 百分点 |
| 营业利润 | $64.8亿 | $19亿 | +240.5% |
| 营业利润率 | 37.3% | 12.1% | +25.2 百分点 |
| 净利润 | $42.2亿 | $1.86亿 | +2,169.9% |
| 稀释EPS | $2.38 | $0.10 | +2,296.8% |
| 经营现金流 | – | $70.2亿 | – |
| 资本支出 | – | $3.81亿 | – |
| 自由现金流 | – | $66.4亿 | – |
| R&D | $25.7亿 | $23.2亿 | +10.7% |
| 股权激励费用 | – | $2.09亿 | – |
实际 vs 一致预期
2026-10-30| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $174亿 | $173亿 | +0.5% |
| EPS(一致预期口径) | $3.82 | $3.73 | +2.4% |
来自2026-10-30发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| SKYRIZI | $55.1亿 | +24.5% | 34.3% | $197亿 | +32.8% | |
| H U M I R A | $7.56亿 | -35.9% | 4.7% | $36.8亿 | -40.7% | |
| RINVOQ | $25.3亿 | +24.5% | 15.7% | $92亿 | +27.9% | |
| Other Products | $11.1亿 | +83.9% | 6.9% | $34.1亿 | +20.6% | |
| Vraylar | $10.7亿 | +19.0% | 6.7% | $39.3亿 | +13.5% | |
| Botox Therapeutic | $10.4亿 | +12.3% | 6.5% | $40.3亿 | +14.5% | |
| Imbruvica | $5.32亿 | -29.4% | 3.3% | $24.7亿 | -22.2% | |
| VENCLEXTA | $7.71亿 | +11.6% | 4.8% | $29.8亿 | +10.8% | |
| Botox Cosmetic | $7.28亿 | +5.2% | 4.5% | $27.5亿 | +5.5% | |
| Ubrelvy | $3.92亿 | +16.0% | 2.4% | $14.2亿 | +23.8% | |
| MAVYRET | $2.95亿 | -21.3% | 1.8% | $12.8亿 | +0.6% | |
| Qulipta | $3.5亿 | +31.1% | 2.2% | $12.2亿 | +46.0% | |
| Juvederm Collection | $2.45亿 | -5.8% | 1.5% | $9.79亿 | -4.8% | |
| Other Aesthetics | $3.09亿 | -5.5% | 1.9% | $12.2亿 | -5.1% | |
| Linzess/Constella | $2.95亿 | +14.3% | 1.8% | $10.8亿 | +23.6% | |
| Other Eye Care | – | – | – | – | – | |
| Ozurdex | – | – | – | – | – | |
| Other Neuroscience | $1.17亿 | +112.7% | 0.7% | $3.35亿 | +12.4% | |
| Lumigan/Ganfort | – | – | – | – | – | |
| Duodopa | – | – | – | – | – | |
| Alphagan/Combigan | – | – | – | – | – |
按地区划分的营收
占总额比例| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $47.7亿 | +24.0% | 86.2% | $479亿 | +59.3% | |
| Non-US | $7.6亿 | +31.0% | 13.8% | $21亿 | -87.8% |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 自由现金流
- –
- 股东回报 / FCF
- –
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | 50.6× | 54.5× | 20.9× – 96.4× |
| EV / EBITDA | 24.2× | 19.5× | 12.8× – 26.6× |
| EV / 营收 | 8.9× | 6.3× | 5.5× – 7.7× |
| 股价 / FCF | 28.6× | 15.1× | 10.9× – 22.8× |
| 股价 / 净资产 | -88.0× | 38.3× 5年中的4年 | 15.6× – 94.5× |
| FCF收益率 | 3.5% | 7.2% | 4.4% – 9.2% |
| 投入资本回报率 | 18.6% | 11.6% | 8.9% – 14.0% |
| 净资产收益率 | -223.7% | 38.0% | -129.2% – 128.7% |
分析师
一致目标价 $294.00 (-0.3%)
区间 $235.00 – $325.00 · 评级 Buy
强烈买入0
买入31
持有12
卖出1
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $676亿 | +10.5% | $13.94 | +488.2% | 21.2× | 12 |
| FY2027 | $736亿 | +8.8% | $16.26 | +16.6% | 18.1× | 15 |
| FY2028 | $793亿 | +7.7% | $17.99 | +10.7% | 16.4× | 8 |
| FY2029 | $838亿 | +5.7% | $19.72 | +9.6% | 15.0× | 5 |
| FY2030 | $857亿 | +2.3% | $20.98 | +6.4% | 14.1× | 5 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
AbbVie Inc.在近期10-Q / 10-K文件中标记的全部270项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable and Accrued Liabilities, Current | $333亿 | $322亿 | +3.3% | $347亿 | $319亿 | +8.7% |
| Accounts Payable, Current | $35.9亿2025-12-31 | $29.5亿 | +22.0% | $35.9亿 | $29.5亿 | +22.0% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $138亿 | $126亿 | +9.4% | $126亿 | $109亿 | +15.3% |
| Accrued Income Taxes, Noncurrent | $3.64亿2025-12-31 | $12.6亿 | -71.1% | $3.64亿 | $12.6亿 | -71.1% |
| Accrued Royalties, Current | $4.53亿2025-12-31 | $5.27亿 | -14.0% | $4.53亿 | $5.27亿 | -14.0% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $81.6亿 | $76.5亿 | +6.6% | $79亿 | $71.3亿 | +10.8% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$11.6亿 | -$15.4亿 | +24.7% | -$11.4亿 | -$19.3亿 | +40.6% |
| Additional Paid in Capital, Common Stock | $232亿 | $220亿 | +5.3% | $225亿 | $213亿 | +5.4% |
| Advertising Expense | – | – | – | $21亿 | $21亿 | 0.0% |
| Amortization of Intangible Assets | $17亿 | $19亿 | -10.5% | $73.8亿 | $76.2亿 | -3.2% |
| Assets | $1350亿 | $1370亿 | -1.5% | $1340亿 | $1350亿 | -0.9% |
| Assets, Current | $337亿 | $293亿 | +15.1% | $291亿 | $256亿 | +13.6% |
| Business Acquisition, Pro Forma Net Income (Loss) | – | – | – | $45.6亿2024-12-31 | $28.6亿 | +59.5% |
| Business Acquisition, Pro Forma Revenue | – | – | – | $564亿2024-12-31 | $547亿 | +3.1% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | $15.2亿 | $28亿 | -45.7% | $65亿 | $37.7亿 | +72.2% |
| Business Combination, Contingent Consideration, Liability, Current | $34.6亿2025-12-31 | $25.9亿 | +33.4% | $34.6亿 | $25.9亿 | +33.4% |
| Business Combination, Contingent Consideration, Liability, Noncurrent | $219亿2025-12-31 | $191亿 | +14.9% | $219亿 | $191亿 | +14.9% |
| Cash and Cash Equivalents, at Carrying Value | $65.7亿 | $64.7亿 | +1.6% | $52.3亿 | $55.2亿 | -5.3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $65.7亿 | $64.7亿 | +1.6% | $52.3亿 | $55.2亿 | -5.3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$28.2亿 | $12.9亿 | -318.4% | -$2.95亿 | -$72.9亿 | +96.0% |
| Common Stock, Dividends, Per Share, Declared | $1.73 | $1.64 | +5.5% | $6.65 | $6.29 | +5.7% |
| Common Stock, Par or Stated Value Per Share | $0.01 | $0.01 | 0.0% | $0.01 | $0.01 | 0.0% |
| Common Stock, Shares Authorized | 40亿 | 40亿 | 0.0% | 40亿 | 40亿 | 0.0% |
| Common Stock, Shares, Issued | 18.4亿 | 18.4亿 | +0.4% | 18.4亿 | 18.3亿 | +0.4% |
| Common Stock, Value, Outstanding | $1800万 | $1800万 | 0.0% | $1800万 | $1800万 | 0.0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $300万 | $300万 | 0.0% | $700万 | $800万 | -12.5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $36.1亿 | $11.4亿 | +215.9% | $50.1亿 | $46.6亿 | +7.5% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $36.1亿 | $11.5亿 | +215.4% | $50.1亿 | $46.7亿 | +7.5% |
| Cost of Goods and Services Sold | $42.9亿 | $43.5亿 | -1.3% | $182亿 | $169亿 | +7.7% |
| Costs and Expenses | $106亿 | $105亿 | +0.3% | $461亿 | $472亿 | -2.4% |
| Current Federal Tax Expense (Benefit) | – | – | – | $12.3亿 | -$3.31亿 | +471.6% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $16.3亿 | $12.1亿 | +34.4% |
| Current Income Tax Expense (Benefit) | – | – | – | $28.6亿 | $8.79亿 | +224.9% |
| Debt and Lease Obligation | $650亿2025-12-31 | $671亿 | -3.2% | $650亿 | $671亿 | -3.2% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$6100万 | -$13亿 | +95.3% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$4.31亿 | -$1.46亿 | -195.2% |
| Deferred Income Tax Expense (Benefit) | -$1.95亿 | -$2.72亿 | +28.3% | -$4.92亿 | -$14.5亿 | +66.0% |
| Deferred Income Tax Liabilities, Net | $22.8亿 | $25.5亿 | -10.8% | $23.9亿 | $25.8亿 | -7.4% |
| Deferred Tax Assets, Gross | $212亿2025-12-31 | $209亿 | +1.7% | $212亿 | $209亿 | +1.7% |
| Deferred Tax Assets, Net of Valuation Allowance | $62亿2025-12-31 | $60.4亿 | +2.7% | $62亿 | $60.4亿 | +2.7% |
| Deferred Tax Assets, Other | $25亿2025-12-31 | $22.2亿 | +12.7% | $25亿 | $22.2亿 | +12.7% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $7400万2025-12-31 | $2.15亿 | -65.6% | $7400万 | $2.15亿 | -65.6% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | $11.3亿2025-12-31 | $12.5亿 | -9.6% | $11.3亿 | $12.5亿 | -9.6% |
| Deferred Tax Assets, Valuation Allowance | $150亿2025-12-31 | $148亿 | +1.3% | $150亿 | $148亿 | +1.3% |
| Deferred Tax Liabilities, Gross | $24.8亿2025-12-31 | $29.9亿 | -17.0% | $24.8亿 | $29.9亿 | -17.0% |
| Deferred Tax Liabilities, Intangible Assets | $15.3亿2025-12-31 | $19.7亿 | -22.3% | $15.3亿 | $19.7亿 | -22.3% |
| Deferred Tax Liabilities, Investments | $3.22亿2025-12-31 | $3.02亿 | +6.6% | $3.22亿 | $3.02亿 | +6.6% |
| Deferred Tax Liabilities, Other | $6.3亿2025-12-31 | $7.18亿 | -12.3% | $6.3亿 | $7.18亿 | -12.3% |
| Defined Benefit Plan, Accumulated Benefit Obligation | $87亿2025-12-31 | $81亿 | +7.4% | $87亿 | $81亿 | +7.4% |
| Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation | $7.49亿2025-12-31 | $7.75亿 | -3.4% | $7.49亿 | $7.75亿 | -3.4% |
| Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets | $9900万2025-12-31 | $2.65亿 | -62.6% | $9900万 | $2.65亿 | -62.6% |
| Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation | $6.47亿2025-12-31 | $5.27亿 | +22.8% | $6.47亿 | $5.27亿 | +22.8% |
| Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets | $9900万2025-12-31 | $9400万 | +5.3% | $9900万 | $9400万 | +5.3% |
| Depreciation | $1.94亿 | $1.86亿 | +4.3% | $7.62亿 | $7.64亿 | -0.3% |
| Derivative Asset, Fair Value, Gross Asset | $2.79亿 | $1.01亿 | +176.2% | $9100万 | $3.13亿 | -70.9% |
| Derivative Liability, Fair Value, Gross Liability | $2.84亿 | $8.8亿 | -67.7% | $5.4亿 | $2.66亿 | +103.0% |
| Dividends Payable, Current | $31亿2025-12-31 | $29.4亿 | +5.6% | $31亿 | $29.4亿 | +5.6% |
| Dividends, Common Stock, Cash | $30.7亿 | $29.1亿 | +5.5% | $118亿 | $112亿 | +5.7% |
| Earnings Per Share, Basic | $2.04 | $0.52 | +292.3% | $2.37 | $2.40 | -1.2% |
| Earnings Per Share, Diluted | $2.03 | $0.52 | +290.4% | $2.36 | $2.39 | -1.3% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标、预期:Financial Modeling Prep。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-01